:: ±Û´äº¯ ::
ÀÌ ¸§
ÆÐ½º¿öµå
À̸ÞÀÏ
ȨÆäÀÌÁö
¿É ¼Ç
html
Á¦ ¸ñ
> > > TADACIP-20 éçÓð¡¸ÚúÑÃò¥áÙΦÎù£¨Priapism£©¡¹怎麼ô¥×⣿ > î¤Ñûàõð¾Úúå·ã¼íÞñ飬ìÔÓøßù××ÞÍ TADACIP-20£¨öâÓ¹ÕÃÞª Tadalafil 20mg£© ãÀë¦ìÔÓøð²å·ËÝÔé Cipla Ltd. õóù¡îÜÍÔù¡òõùÊ٣巡£îÏγ TADACIP-20 ìÔÓøßù××ÞÍùÊÙ£å· ì¤è±ïÒå·üù¡¢öááÜÑÃüùæ¨Ê¦ò¥áÙ 36 á³ãÁîÜ¡¸íþüùð¾ÚúÕô¡¹Ú¤Ù££¬à÷為úÉÒýÑûàõËÇà¼ÚúÑÃÍíÒöî¡礙£¨ED£©îÜâÏàÔ¡£ > æÔ컣¬î¤Ý»ÝÂï×üÏù»£¬Ü×éÄ TADACIP-20 ýʦÒöõóúÞùÖ̸ӣåññìîÜÜùíÂéÄ——ÚúÑÃò¥áÙΦÎù£¨Priapism£©¡£ÜâÙþíâÌ¿ùêì¢ùÊ研ϼâ¦Ëàæ¨×üßÉÌèúУ¬ßÙá¬ú°à°îÏìéúÞßÚîÜê«ìס¢êËúÏàõæ¨ëëÓßÛ°ãÒ£¬幫ð¾ÞÅéÄíºäÌîïÞÅéÄ TADACIP-20 öâÓ¹ÕÃÞªùÊÙ£ > > > ìé¡¢ä§麼ãÀ¡¸ÚúÑÃò¥áÙΦÎù£¨Priapism£©¡¹£¿ > ÐÆËàÚ¸ÏÐù²ÒãΡì¢ùÊü壨AUA£©îÜïÒëù£¬Priapism£¨ò¥áÙàõÚúÑÃñø£© ãÀò¦ëäÌìî¤Ú±áôÓðàõí©Ìù»í¤ò¥áÙÚúÑÃõ±Î¦ 4 á³ãÁì¤ß¾£¬ó¦ÙíÛöí»æÔá¼÷ÜîÜï×üÏ¡£îÏãÀ TADACIP-20 ÜùíÂéÄ ñéпá´Ì¸Ó£âÍØ¡即ô¥×âîÜìéðúßÒüÏ¡£ > > ×üßÉ߾ʦÝÂ為Õ××¾£º > > ÌÀúìàõ Priapism£¨Ischemic£©£º佔á¶êóÜ»ÖÇå³ 95%£¬為ì¢ÖûÐáñø¡£ëäÌìúØúô÷úìäûôò׺¡¢ÌÀ氧£¬å´õ±Î¦ 6 á³ãÁüåÓôöÈðÚòÄÎÕÞÝ¡£ > > ÞªÌÀúìàõ Priapism£¨Non-ischemic£©£º÷×ßÈì×úìηóÜß¿ûäèâÕôÓôöÈ£¬âÌÜôêËÐàßæÙ¤£¬Ó£í¤âÍì¢ÞÔøÄ估¡£ > > ÐÆËà Journal of Urology (2018) ÜÃÓô£¬å´ÚúÑÃò¥áÙõ±Î¦ 24 á³ãÁÚ±ö½Öû£¬90% ì¤ß¾ü´íºüåõóúÞçµÎùàõÚúÑÃÍíÒöî¡礙¡£ > > 죡¢為ù¼Ü×éÄ TADACIP-20 üåõóúÞ Priapism£¿ > TADACIP-20 îÜà÷ÝÂ為 öâÓ¹ÕÃÞª£¨Tadalafil£©£¬áÕåÚ PDE5 åäð¤ð¥£¨Phosphodiesterase type-5 inhibitor£©¡£它ÒöÛ¯鬆ëäÌìúØúô÷øÁüÁÑ¿¡¢õµòäúìäû×µìý£¬Ó¹Óðò¥ÎùÚúÑÃîÜüùÍý¡£ > > Ó£î¤Ù»ÞÁ÷åâ¨ßÒüÏù»£¬å·üùΦ強ûäÓÛÞóì¶ßÈʦÒöÓôöÈúìäûÙíÛöïáßÈüÞ×µ£¬û¡à÷ëäÌìúì×µôò׺¡£ > > ßÈ̸îÜë¯Û¡ê«ì×øÐÎÀ£º > > TADACIP-20 ð¥ÕáΦÍÔ£¨õ±Î¦ØßìíËïì¡ 20mg£© > > ÔÒãÁÞÅéÄÐìöâð¾Úúå·£¨åý Super P-Force¡¢Sildenafil¡¢Levitra£© > > 飲ñÐûäÞÅéÄÔ¸ù¡£¨÷åܬãÀʦ卡ìס¢äÌÞªöâÙ¤£© > > ü´êóúìäûòðÜ»£¨åý鐮ßÒá¬øàÞ¸úì¡¢ÛÜúìÜ»£© > > ÊÜãìÍíÒöáôáßÓôöÈå·ÚªÓÛÞóܨط > > ÐÆËà European Urology (2020) 研ϼ£¬Ü×éÄ PDE5 åäð¤ð¥ýõóúÞ Priapism îÜѦáãá³åÚ 0.1%£¬Ó£å´ùê併úìäûòðÜ»ûäÕ½éÄå·Úª£¬ù¦úÏʦÒö߾㮠5~10 Ûᣠ> > > ß²¡¢ÚúÑÃΦÎùîÜêËúÏàõ > å´ÞÅéÄ TADACIP-20 ìÔÓøßù××ÞÍùÊÙ£å· ýõóúÞÚúÑÃõ±Î¦ 4 á³ãÁÚ±á¼÷Ü£¬ëäÌìÒ®úìäûì×ÌÀ氧üåðãà÷£º > > мÖÔÙ÷Ôæ¨ðþóì > > ëäÌìðÚòÄÌÀúìÎÕÞÝ > > çµÎùàõÚúÑÃÍíÒöî¡礙£¨ED£© > > åññìãÁâÍòäú¼èâΡâ¢âú > > American Journal of Emergency Medicine (2021) ÜÃͱò¦õó£º > å´î¤ 6 á³ãÁÒ®ö½Öû Priapism£¬ü´íºèÇîïüáÜÖÚúÑÃÍíÒöîÜÝïÖÇÍÔÓ¹ 77%£»å´õ±Î¦ 24 á³ãÁÚ±ô¥×⣬üáÜÖáãÐÁí¥ 25%¡£ > > ÞÌ¡¢Û¡ß桸ÚúÑÃò¥áÙΦÎù¡¹ãÁîÜïáü¬ô¥×âÛ°ãÒ > å´Ü×éÄ TADACIP-20 öâÓ¹ÕÃÞªùÊÙ£å· ýõóúÞíþãÁÊàÚúÑã¬ôëØ¡即óõö¢ì¤ù»ÜÆö®£º > > ïÎòá¶êóàõí©Ìæ¨ê¡ÔÑ£¬ÜÁò¥ÕÒð¡¡£ > > ÞÅéÄ冰ݧëäÌìÐÆÝ»£¨Øßó 10~15 ÝÂñ¤£©£¬êóð¾úìηâ¥õê¡£ > > ùØóí»ú¼Ü×éÄò÷Ôå·ûä˽äâå·£¬ì¤ØóåóËÏÜ»ïס£ > > å´ÚúÑÃò¥áÙõ±Î¦ 4 á³ãÁ£¬ëëØ¡即ö¦ì¢¡£ > > î¤ì¢ê£¬ù²ÒãΡì¢ÞÔʦÒöóõéÄì¤ù»ö½ÖûÛ°ãÒ£º > > ëäÌìõÎúìÊõä⣨Aspiration therapy£©£ºõÎõóôò׺úìäûì¤Ë½î¸äâÕô¡£ > > ÏÑÝ»ñ¼ÞÒËÛ氧ãìß¾àÍáÈ£¨Phenylephrine£©£ºõµòäúìηâ¥õê¡£ > > â¢âúìÚ×µ£¨Shunt operation£©£ºöÜÓßåññìûäÚãÜÝàõÜ»ÖÇ¡£ > > > çé¡¢åýù¼çèÛÁ TADACIP-20 ìÚÛ¡ Priapism > 為ùØóó®×¾ÜùíÂéÄî¢óÛ¡ßæ£¬Ëïì¡ÞÅéÄíºñåáúì¤ù»ê«öΣº > > åñÌ«ñåáú TADACIP-20 ð¥Õ᣺ØßìíùÚÜ×ìéó¡£ > > ùØóæ¨Ðìöâð¾Úúå·ÚªûäñÐïñ併éÄ¡£ > > âÏóÞÅéÄʦà»ðô TADACIP-10mg ËÒã·ÎºóÌÚãëë¡£ > > ü´êóØ·àõòðÜ»íº£¨åýÓØÒãÜ»¡¢ÍÔúìä⣩âÍÞÀà»í¿âóì¢ÞÔ¡£ > > ÜÁò¥ÕÞû¿ßæüÀã§Î±£ºÐ®×Èê¡ÔÑ¡¢ùØóè¢å¨æ¨ýå菸¡£ > > ÐÆËà Cipla ð²å·×üßÉíÀÖù£¨2022£©£¬î¤ñåáúì¢ÞÔò¦ãÆÜ×éÄîÜðéÏØñé£¬Û¡ßæÚúÑÃΦÎùûäåññìÜùíÂéÄîÜÝïÖÇî¸åÚ 0.05%¡£ > > > ׿¡¢õÅÌ¿£ºäÌîïÞÅéÄ TADACIP-20£¬ü¬ÜÁàõËíˬ > TADACIP-20£¨öâÓ¹ÕÃÞª 20mg£© ãÀìéγÍÔüù¡¢ò¥Îùó¦äÌîïàõÍÔîÜ ìÔÓøßù××ÞÍùÊ٣巣¬Ó£å´ÞÅéÄÜôÓ×í¤Ê¦ÒöÓôöÈ Priapism£¨ÚúÑÃò¥áÙΦÎù£©¡£ > Ó×õóúÞõ±Î¦ 4 á³ãÁÜô÷ÜîÜÚúÑÃãÁ£¬Ùâù±ãÊ為ì¢ÖûÐáñø£¬ò×öáãüÏ´ù²ÒãΡúð𾡣 > ïáü¬ð¥ÕáÍó𤡢ì¢ÞÔò¦Óôæ¨äÌîïëòãÛ£¬ãÀü¬ÜÁ TADACIP-20 ð¾Úúå· Û¡ýÆõÌÊ¢üùÍýîÜμËõ¡£ > > ßÓμ產ù¡õÏôÀ£ºÑÑóÈõ±ÐääõÕôÓ¹äªüùø¸ ÓìÏÐûõتêÎÌ«Õã¨VIGORA £©â©ÍýÚ«Ï¢éÁïüêÎ 100mg ïáù¡úÅùûÖÕñéì¢ ìÔÓøâíòäÏ¢ïáù¡ù±××ÌÍPriligy(POXET-60)GOODMANëäÌìñòÓÞü¯goodmanÚ¸ÏÐßù××ÞÍCialisê«íûòäÏ¢áÜüùð¾Úú > > æÅãßæóÔÁ£ºTadacip-20 ÞÅéÄæ¨ãýúìηå·ÚªÎßû»íÂéÄ >
¸µÅ© #1
¸µÅ© #2
ÆÄÀÏ÷ºÎ
¿ÞÂÊÀÇ ±ÛÀÚ¸¦ ÀÔ·ÂÇϼ¼¿ä.